Table 2. Clinical course and outcomes of MDR-TB treatment, by HIV status.a .
| HIV-negative | HIV-positive | pc | ||||
| (N = 40)b | (N = 94)b | |||||
| Final outcomes | Cured | 17 (42.5) | 54 (57.5) | 0.3613 | ||
| Treatment completed | 4 (10.0) | 8 (8.5) | ||||
| Died | 17 (42.5) | 29 (30.9) | ||||
| Defaulted | 1 (2.5) | 0 (0.0) | ||||
| Failed | 0 (0.0) | 1 (1.1) | ||||
| Transferred | 1 (2.5) | 2 (2.1) | ||||
| Treatment duration (months) | 22.4 (21.6–24.0) | 22.9 (21.8–23.9) | 0.8838 | |||
| Time on parenteral agent (months)d | 10.2 (9.4–11.3) | 10.5 (0.3–11.4) | 0.6370 | |||
| Time to culture conversion (days) (N = 84)e | 59 (49–89) | 66 (38–98) | 0.6398 | |||
| Time to smear conversion (days) (N = 79)e | 48 (23–63) | 66.5 (31–97) | 0.0571 | |||
| Time to death (days) | 136 (86–340) | 110 (66–208) | 0.4169 | |||
a
Table values are median (IQR) for continuous variables and n (column %) for categorical variables.
b
Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to rounding.
c
P-value is for Wilcoxon rank sum test (continuous variables) or Fisher’s exact test (categorical variables).
d
Calculated among those who completed the intensive phase of treatment.
e
Calculated among those who had positive results at baseline (within one month before or one week after initiation of MDR-TB treatment).